Certara, Inc.
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | $93.30M | $-0.04 | $0.08 |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | $106.90M | $-0.06 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $103.60M | $-0.04 | $0.09 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $104.60M | $0.01 | $0.14 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $104.60M | $-0.01 | $0.07 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 14, 2025 | Before market open | $106.00M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 15, 2025 | Before market open | $99.70M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $94.80M | $-0.01 | $0.13 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted diluted earnings per share for Continuing Operations, excluding the Regulatory and Medical Writing businessnon-GAAP | Full year | $0.31 to $0.36 | Lowered |
| Fully diluted shares | full year 2026 | 155 to 157 | Lowered |
| adjusted EBITDA margin for Continuing Operations, excluding the Regulatory and Medical writing businessnon-GAAP | Full year 2026 | 29% to 31% | New |
| Revenue growth for Continuing Operations, excluding the Regulatory and Medical Writing businessnon-GAAP | full year 2026 | 0% to 4% growth | New |
| revenuenon-GAAP | full year 2026 | $367.00M to $382.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Certara filed with the SEC
Certara Reports Second Quarter 2026 Financial Results
Results of operations · EX-99 to Form 8-K
Certara Reports First Quarter 2026 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
Results of operations · EX-99 to Form 8-K
Certara Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports Preliminary First Quarter 2025 Financial Results;
Material agreement · Results of operations · EX-99.1 to Form 8-K
Certara Reports Fourth Quarter 2024 Financial Results
Results of operations · EX-99 to Form 8-K
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99 to Form 8-K
Certara Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports Second Quarter 2024 Financial Results
Results of operations · EX-99 to Form 8-K
Certara to Acquire Chemaxon to Strengthen Drug
Regulation FD disclosure · EX-99.1 to Form 8-K
Certara Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports Fourth Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Certara Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Certara Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Certara Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Arsenal Capital Partners Increases Investment
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Certara Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Certara Completes Acquisition of Pinnacle 21
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K